Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has secured funding from the Bill & Melinda Gates Foundation (“the Gates Foundation” or “the foundation”).

The funding is comprised of a $5 million equity investment to advance Owlstone’s Breath Biopsy platform and $1.5 million in grant funding to develop breath-based diagnostics and identify breath biomarkers for tuberculosis (TB) and HIV.

Owlstone, with support from the foundation, is interested in developing new cost-effective detection technologies for volatile organic compounds (VOCs) that could serve as markers of diseases that disproportionately affect the developing world. With the new funding, Owlstone seeks to understand whether this approach is suitable for TB and HIV detection and to explore a path by which breath-based testing could be deployed for rapid screening and earlier diagnosis.

Early diagnosis is a critical determinant of health outcomes. By enabling swift and non-invasive detection of disease, breath analysis has the potential to save lives and dramatically reduce the burden of illness in resource-constrained settings. This investment by the Gates Foundation is testament to how Owlstone is uniquely positioned to transform infectious disease diagnosis through our Breath Biopsy platform. The funds will accelerate both the discovery and validation of VOC biomarkers, and the development of a fieldable, low cost, simple to use device.”

Billy Boyle, co-founder and CEO at Owlstone Medical

The $5 million equity investment will support advancements of the Breath Biopsy platform, including expansion of the Breath Biopsy VOC Atlas1 database and for development of a remote-use real-time breath analyzer. This funding component will be the first time the foundation has taken an equity position in a breath diagnostics company.

The $1.5 million in grant funding to support the identification of breath biomarkers will be used across two projects:

  • TB: In partnership with the University of Cape Town, South Africa, Owlstone aims to identify a panel of on-breath candidate VOC biomarkers that differentiate TB subjects from healthy controls and to develop breath diagnostic approaches based on exploiting the metabolic features of TB using in vitro approaches.
  • HIV: Working with investigators from Imperial College, UK, and Oxford University, UK, Owlstone will analyze VOCs from blood samples from subjects with HIV and will work to identify a panel of on-breath candidate VOC biomarkers that correlate with HIV viral load.

The data collected will also be used to populate Owlstone’s Breath Biopsy VOC Atlas further in both areas.

Activities complementary to this project are underway with the US Department of Defense2 (the ‘EXHALE’ project) where Owlstone is developing a handheld device capable of non-invasive detection of pre-symptomatic respiratory infectious disease, providing further support for Owlstone’s ability to advance the foundation’s mission.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Owlstone Medical Ltd. (2024, April 25). Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease. News-Medical. Retrieved on May 18, 2024 from https://www.news-medical.net/news/20240425/Owlstone-Medical-secures-2465-million-to-support-development-of-breath-based-diagnostics-for-infectious-disease.aspx.

  • MLA

    Owlstone Medical Ltd. "Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease". News-Medical. 18 May 2024. <https://www.news-medical.net/news/20240425/Owlstone-Medical-secures-2465-million-to-support-development-of-breath-based-diagnostics-for-infectious-disease.aspx>.

  • Chicago

    Owlstone Medical Ltd. "Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease". News-Medical. https://www.news-medical.net/news/20240425/Owlstone-Medical-secures-2465-million-to-support-development-of-breath-based-diagnostics-for-infectious-disease.aspx. (accessed May 18, 2024).

  • Harvard

    Owlstone Medical Ltd. 2024. Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease. News-Medical, viewed 18 May 2024, https://www.news-medical.net/news/20240425/Owlstone-Medical-secures-2465-million-to-support-development-of-breath-based-diagnostics-for-infectious-disease.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Every breath counts; Utilizing breath biopsy technology to detect disease early